Enbrel (etanercept) is a prescription brand-name medication. It’s approved by the Food and Drug Administration (FDA) to treat the following conditions: For each of these conditions, Enbrel is ...

THOUSAND OAKS, Calif. and COLLEGEVILLE, Pa., Feb. 4, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) and Pfizer Inc. (NYSE: PFE) today announced results from a new trial that demonstrated Enbrel® ...

SEATTLE, WA – Immunex Corporation (Nasdaq: IMNX) and Wyeth-Ayerst Laboratories, a division of American Home Products (NYSE: AHP) announced today that the U.S. Food and Drug Administration (FDA) has ...

THOUSAND OAKS, Calif., Nov. 22, 2011 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today issued the following statement: Amgen today announced the issuance of U.S. Patent No. 8,063,182 related to Enbrel ® ...

Whether starting or maintaining treatment, the Embark App has multiple features that can help patients on ENBREL throughout their treatment experience. As the healthcare industry continues to evolve ...

SAN FRANCISCO, November 11, 2001– Data from a Phase 2 clinical study of ENBREL® (etanercept) in ankylosing spondylitis will be presented this week at the 65th Annual Scientific Meeting of the American ...

ZUG, Switzerland--(BUSINESS WIRE)--The joint venture between Biogen (NASDAQ:BIIB) and Samsung BioLogics, Samsung Bioepis, has been granted European Commission (EC) approval for BENEPALI® , an ...

INCHEON, Korea--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. today announced that the US Food and Drug Administration (FDA) has approved ETICOVO™ (etanercept-ykro), a biosimilar referencing ENBREL ® ...

On February 7, 2018, Lupin announced positive results from a Phase III clinical trial for its etanercept biosimilar candidate, YB113. YB113 is being developed by YL Biologics, a joint venture of Lupin ...

Please provide your email address to receive an email when new articles are posted on . Approximately 70% of patients with juvenile idiopathic arthritis who are re-treated with etanercept achieve ...

The pharmaceutical company Amgen is suing the Colorado Prescription Drug Affordability Board after the price of one of its ...